Anteris Technologies Approves ASX Waiver Proposal

The latest announcement is out from Anteris Technologies Global Corp. ( (AVR) ).

On September 29, 2025, Anteris Technologies Global Corp. held a special meeting where stockholders approved the ASX Waiver Proposal, allowing the company to issue new securities without stockholder approval under certain conditions. Additionally, the company provided an update on its PARADIGM Trial, with patient enrollment now expected to commence in the fourth quarter of 2025 following additional information requests from the FDA, demonstrating the company’s ongoing commitment to advancing its heart valve technology globally.

The most recent analyst rating on (AVR) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on Anteris Technologies Global Corp. stock, see the AVR Stock Forecast page.

Spark’s Take on AVR Stock

According to Spark, TipRanks’ AI Analyst, AVR is a Neutral.

Anteris Technologies Global Corp. has a low overall stock score due to significant financial challenges, including declining revenues and persistent losses. The technical analysis indicates a bearish trend, and the valuation is unattractive with a negative P/E ratio. However, the recent ASX waiver for securities issuance is a positive corporate event, providing potential strategic opportunities.

To see Spark’s full report on AVR stock, click here.

More about Anteris Technologies Global Corp.

Anteris Technologies Global Corp. operates in the medical technology industry, focusing on the development and commercialization of innovative heart valve solutions, including the DurAVR® THV System. The company is engaged in advancing its products through global pivotal trials and regulatory submissions.

Average Trading Volume: 191,821

Technical Sentiment Signal: Hold

Current Market Cap: $154.7M

For detailed information about AVR stock, go to TipRanks’ Stock Analysis page.